Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned a consensus recommendation of “Buy” from the eleven analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $66.00.

A number of equities analysts recently commented on MAZE shares. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, Truist Financial dropped their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th.

Maze Therapeutics Trading Up 0.1%

NASDAQ MAZE opened at $27.31 on Wednesday. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics has a 12 month low of $12.81 and a 12 month high of $53.65. The company’s fifty day moving average price is $27.63 and its two-hundred day moving average price is $33.32.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). As a group, research analysts predict that Maze Therapeutics will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. The trade was a 22.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. This represents a 59.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 141,470 shares of company stock worth $3,902,714 over the last 90 days. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the 4th quarter valued at approximately $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Maze Therapeutics during the 2nd quarter worth $48,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.